Abstract
Introduction of dystrophin by gene transfer into the dystrophic muscles of Duchenne muscular dystrophy (DMD) patients has the possibility of triggering an immune response as many patients will not have been exposed to some (or all) of the epitopes of dystrophin. This could in turn lead to cytotoxic destruction of transfected muscle fibres. We assessed such concerns in the dystrophin-deficient mdx mouse using plasmid DNA as the gene transfer system. This avoids complications associated with the administration of viral proteins. Gene transfer of cDNAs encoding mouse full-length or a truncated minidystrophin did not evoke either a humoral or cytotoxic immune response. Mdx mice may be tolerant due to the presence of rare ‘revertant’ dystrophin-positive fibres in their skeletal muscles. In contrast, gene transfer of human full-length or minidystrophin provoked both humoral and cytotoxic responses leading to destruction of the transfected fibres. These experiments demonstrate the potential risk of deleterious effects following gene therapy in DMD patients and lead us to suggest that patients enrolled in gene therapy trials should ideally have small, preferably point, mutations and evidence of ‘revertant’ dystrophin-positive muscle fibres.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Koenig M et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion Am J Hum Genet 1989 45: 498–506
England SB et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin Nature 1990 343: 180–182
Emery AEH . Duchenne Muscular Dystrophy. Oxford Monog. Med. Genet No 15, Oxford Medical 1987
Nicholson LV et al. Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 1. Trends across the clinical groups J Med Genet 1993 30: 728–736
Partridge TA et al. Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts Nature 1989 337: 176–179
Acsadi G et al. Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs Nature 1991 352: 815–818
Vincent N et al. Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene Nat Genet 1993 5: 130–134
Howell JM et al. High-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscle of dystrophic dogs: prolongation of expression with immunosuppression Hum Gene Ther 1998 9: 629–634
Yang L et al. Adenovirus-mediated dystrophin minigene transfer improves muscle strength in adult dystrophic (MDX) mice Gene Therapy 1998 5: 369–379
Bittner RE et al. Serum antibodies to the deleted dystrophin sequence after cardiac transplantation in a patient with Becker's muscular dystrophy New Engl J Med 1995 333: 732–733
Huard J et al. Human myoblast transplantation between immunohistocompatible donors and recipients produces immune reactions Transplant Proc 1992 24: 3049–3051
Tremblay JP et al. Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy Cell Transplant 1993 2: 99–112
Bittner RE et al. Coisogenic all-plus-one immunization: a model for identifying missing proteins in null-mutant conditions. Antibodies to dystrophin in mdx mouse after transplantation of muscle from normal coisogenic donor Neuropediatrics 1994 25: 176–182
Vilquin JT et al. Successful histocompatible myoblast transplantation in dystrophin-deficient mdx mouse despite the production of antibodies against dystrophin J Cell Biol 1995 131: 975–988
Lochmuller H et al. Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice Gene Therapy 1996 3: 706–716
Nudel U et al. Duchenne muscular dystrophy gene product is not identical in muscle and brain Nature 1989 337: 76–78
Gorecki DC et al. Expression of four alternative dystrophin transcripts in brain regions regulated by different promoters Hum Mol Genet 1992 1: 505–510
Bakker E, Van Ommen GJB . Duchenne and Becker Muscular Dystrophy (DMD and BMD). In: Emery AEH (ed) Neuromuscular Disorders: Clinical and Molecular Genetics John Wiley and Sons: Chichester 1998 59–85
Nishio H et al. Identification of a novel first exon in the human dystrophin gene and of a new promoter located more than 500 kb upstream of the nearest known promoter J Clin Invest 1994 94: 1037–1042
Winder SJ . The membrane-cytoskeleton interface: the role of dystrophin and utrophin J Muscle Res Cell Motil 1997 18: 617–629
Bulfield G, Siller WG, Wight PA, Moore KJ . X chromosome-linked muscular dystrophy (mdx) in the mouse Proc Natl Acad Sci USA 1984 81: 1189–1192
Sicinski P et al. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation Science 1989 244: 1578–1580
Hoffman EP, Morgan JE, Watkins SC, Partridge TA . Somatic reversion/suppression of the mouse mdx phenotype in vivo J Neurol Sci 1990 99: 9–25
Wilton SD, Dye DE, Laing NG . Dystrophin gene transcripts skipping the mdx mutation Muscle Nerve 1997 20: 728–734
Partridge T, Lu QL, Morris G, Hoffman E . Is myoblast transplantation effective? Nature Med 1998 4: 1208–1209
Roberts RG, Gardner RJ, Bobrow M . Searching for the 1 in 2,400,000: a review of dystrophin gene point mutations Hum Mutat 1994 4: 1–11
Burrow KL et al. Dystrophin expression and somatic reversion in prednisone-treated and untreated Duchenne dystrophy. CIDD Study Group Neurology 1991 41: 661–666
Chelly J et al. Effect of dystrophin gene deletions on mRNA levels and processing in Duchenne and Becker muscular dystrophies Cell 1990 63: 1239–1248
Cox GA et al. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity Nature 1993 364: 725–729
Wells KE et al. Immune responses, not promoter inactivation, are responsible for decreased long-term expression following plasmid gene transfer into skeletal muscle FEBS Lett 1997 407: 164–168
Wells DJ et al. Evaluation of plasmid DNA for in vivo gene therapy: factors affecting the number of transfected fibers J Pharm Sci 1998 87: 763–768
Hohlfeld R, Engel AG . The immunobiology of muscle Immunol Today 1994 15: 269–274
Ulmer JB et al. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells Immunology 1996 89: 59–67
Loirat D et al. Muscle-specific expression of hepatitis B surface antigen: no effect on DNA-raised immune responses Virology 1999 260: 74–83
Ohtsuka Y et al. Dystrophin acts as a transplantation rejection antigen in dystrophin-deficient mice: implication for gene therapy J Immunol 1998 160: 4635–4640
Wells DJ et al. Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy Hum Mol Genet 1995 4: 1245–1250
Brennan KJ, Hardeman EC . Quantitative analysis of the human alpha-skeletal actin gene in transgenic mice J Biol Chem 1993 268: 719–725
Phelps SF et al. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice Hum Mol Genet 1995 4: 1251–1258
Ishikawa Y, Ishikawa Y, Minami R . Quantitative estimation of dystrophin protein: a sensitive and convenient ‘two-antibody sandwich’ ELISA Tohoku J Exp Med 1996 180: 57–63
Nicholson LV et al. Dystrophin in skeletal muscle. I. Western blot analysis using a monoclonal antibody J Neurol Sci 1989 94: 125–136
Acknowledgements
We wish to thank the following: David Baker (UCL, London) for the anti-CD8 antibody; Terry Partridge (MRC CSC, London) for the founding stock of our mdx-nude colony; Jeff Chamberlain (Michigan) for the mouse dystrophin plasmids; Kay Davies and Don Love (Oxford) and George Dickson (Royal Holloway, London) for the human dystrophin cDNAs; Louise Anderson (Newcastle) for the anti-dystrophin monoclonal antibodies; Serge Braun (Transgene, Strasbourg) for the alternative human full-length dystrophin plasmid and Jill McMahon (Gene Targeting Unit) for advice on histology and imaging. This work was funded by the MRC, the Muscular Dystrophy Campaign and the Wellcome Trust.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ferrer, A., Wells, K. & Wells, D. Immune responses to dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Gene Ther 7, 1439–1446 (2000). https://doi.org/10.1038/sj.gt.3301259
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301259
Keywords
This article is cited by
-
In Vivo Genome Engineering for the Treatment of Muscular Dystrophies
Current Stem Cell Reports (2020)
-
Immunoglobulin therapy ameliorates the phenotype and increases lifespan in the severely affected dystrophin–utrophin double knockout mice
European Journal of Human Genetics (2017)
-
Effect of rapamycin on immunity induced by vector-mediated dystrophin expression in mdx skeletal muscle
Scientific Reports (2012)
-
Effects of irradiating adult mdx mice before full-length dystrophin cDNA transfer on host anti-dystrophin immunity
Gene Therapy (2010)
-
Correction of Multiple Striated Muscles in Murine Pompe Disease Through Adeno-associated Virus–mediated Gene Therapy
Molecular Therapy (2008)